Sg Americas Securities, LLC Kezar Life Sciences, Inc. Transaction History

Sg Americas Securities, LLC

  • $17.2 Billion
  • Q2 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024
SELL
$0.8 - $1.05 $15,461 - $20,293
-19,327 Reduced 43.97%
24,623 $22,000
Q4 2023

Jan 12, 2024
BUY
$0.72 - $1.15 $7,998 - $12,775
11,109 Added 33.83%
43,950 $42,000
Q3 2023

Oct 13, 2023
BUY
$1.08 - $2.54 $35,468 - $83,416
32,841 New
32,841 $39,000
Q1 2023

Apr 28, 2023
BUY
$3.13 - $7.31 $6,817 - $15,921
2,178 Added 11.37%
21,338 $67,000
Q4 2022

Feb 02, 2023
BUY
$6.39 - $8.8 $9,335 - $12,856
1,461 Added 8.25%
19,160 $135,000
Q3 2022

Oct 31, 2022
SELL
$7.99 - $10.75 $3,739 - $5,031
-468 Reduced 2.58%
17,699 $152,000
Q2 2022

Jul 29, 2022
BUY
$4.58 - $17.13 $47,870 - $179,042
10,452 Added 135.48%
18,167 $150,000
Q1 2022

Apr 29, 2022
SELL
$12.3 - $18.33 $3.32 Million - $4.95 Million
-269,898 Reduced 97.22%
7,715 $128,000
Q4 2021

Feb 07, 2022
BUY
$7.44 - $16.72 $1.89 Million - $4.25 Million
254,132 Added 1082.29%
277,613 $4.64 Million
Q3 2021

Nov 01, 2021
BUY
$4.85 - $9.73 $113,882 - $228,470
23,481 New
23,481 $203,000
Q3 2020

Nov 09, 2020
SELL
$4.36 - $5.5 $61,920 - $78,111
-14,202 Closed
0 $0
Q2 2020

Jul 20, 2020
BUY
$3.6 - $7.75 $12,283 - $26,443
3,412 Added 31.62%
14,202 $74,000
Q1 2020

Apr 30, 2020
BUY
$2.77 - $5.75 $29,888 - $62,042
10,790 New
10,790 $47,000

Others Institutions Holding KZR

# of Institutions
83
Shares Held
39.6M
Call Options Held
3.2K
Put Options Held
700
View Full List

About Kezar Life Sciences, Inc.

KZR Quotes by TradingView
  • Ticker KZR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,369,504
  • Market Cap $36.9M
  • Description
  • Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...
More about KZR
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email